COPD AWARENESS SURVEY: DO BELGIAN PULMONARY PHYSICIANS COMPLY WITH THE GOLD GUIDELINES 2010?

Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often undertreated in the general population. A survey of 17 structured questions, delivered to all Belgian pulmonary physicians (PPs) (116 responses), evaluated diagnosis and treatment strategies in accordance with t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta clinica belgica (English ed. Online) Jg. 68; H. 5; S. 325 - 340
Hauptverfasser: Decramer, M, Brusselle, G, Buffels, J, Corhay, JL, De Backer, W, Degryse, JM, Janssens, W, Marchand, E, Van den Brande, P, Vincken, W, Gayan-Ramirez, G, Van Craenendonck, V, Vandenberghe, H, De Vuyst, P
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Taylor & Francis 01.09.2013
Taylor & Francis Ltd
Taylor and Francis
Schlagworte:
ISSN:1784-3286, 2295-3337, 2295-3337
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often undertreated in the general population. A survey of 17 structured questions, delivered to all Belgian pulmonary physicians (PPs) (116 responses), evaluated diagnosis and treatment strategies in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010 and assessed opinions about the importance of diurnal variation of COPD symptoms. All COPD diagnoses (37% new cases) were spirometry confirmed. Main diagnostic parameters were symptoms (99%), external risk factors (99%), clinical examination (97%), exacerbations (96%) and patient mobility (96%). FEV 1 (forced expiratory volume in 1s) (97%) or FEV 1 /FVC (ratio of FEV 1 to forced vital capacity) (93%) were used most to assess diagnosis and severity. The 3 most important therapeutic objectives were symptom relief, preventing exacerbations, and improving quality of life; if these were not reached, the preferred strategy (60% of PPs) was adding another medication. Treatment strategies varied with COPD stage: short-acting β2-agonists (90%) and short-acting anti-cholinergics (59%) were used for GOLD I disease, whereas for higher stages long-acting β2-agonists (36-48%) and long-acting anti-cholinergics (79%) were given with inhaled corticosteroids (21-67%). Symptoms were perceived to vary throughout the day, affecting quality of life (97%) and mobility (89%). In particular, respiratory symptoms were more severe in the morning (51-92%), leading PPs to adapt treatment (69%). This survey demonstrated that management of COPD by PPs in Belgium is generally in line with the GOLD guidelines 2010 and that they perceive morning symptoms as being frequent and having an impact on patient's life.
AbstractList Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often undertreated in the general population. A survey of 17 structured questions, delivered to all Belgian pulmonary physicians (PPs) (116 responses), evaluated diagnosis and treatment strategies in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010 and assessed opinions about the importance of diurnal variation of COPD symptoms. All COPD diagnoses (37% new cases) were spirometry confirmed. Main diagnostic parameters were symptoms (99%), external risk factors (99%), clinical examination (97%), exacerbations (96%) and patient mobility (96%). FEV 1 (forced expiratory volume in 1s) (97%) or FEV 1 /FVC (ratio of FEV 1 to forced vital capacity) (93%) were used most to assess diagnosis and severity. The 3 most important therapeutic objectives were symptom relief, preventing exacerbations, and improving quality of life; if these were not reached, the preferred strategy (60% of PPs) was adding another medication. Treatment strategies varied with COPD stage: short-acting β2-agonists (90%) and short-acting anti-cholinergics (59%) were used for GOLD I disease, whereas for higher stages long-acting β2-agonists (36-48%) and long-acting anti-cholinergics (79%) were given with inhaled corticosteroids (21-67%). Symptoms were perceived to vary throughout the day, affecting quality of life (97%) and mobility (89%). In particular, respiratory symptoms were more severe in the morning (51-92%), leading PPs to adapt treatment (69%). This survey demonstrated that management of COPD by PPs in Belgium is generally in line with the GOLD guidelines 2010 and that they perceive morning symptoms as being frequent and having an impact on patient's life.
Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often under-treated in the general population. A survey of 17 structured questions, delivered to all Belgian pulmonary physicians (PPs) (116 responses), evaluated diagnosis and treatment strategies in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010 and assessed opinions about the importance of diurnal variation of COPD symptoms. All COPD diagnoses (37% new cases) were spirometry confirmed. Main diagnostic parameters were symptoms (99%), external risk factors (99%), clinical examination (97%), exacerbations (96%) and patient mobility (96%). FEV1 (forced expiratory volume in 1s) (97%) or FEV1/FVC (ratio of FEV1 to forced vital capacity) (93%) were used most to assess diagnosis and severity. The 3 most important therapeutic objectives were symptom relief, preventing exacerbations, and improving quality of life; if these were not reached, the preferred strategy (60% of PPs) was adding another medication. Treatment strategies varied with COPD stage: short-acting beta2-agonists (90%) and short-acting anti-cholinergics (59%) were used for GOLD I disease, whereas for higher stages long-acting beta2-agonists (36-48%) and long-acting anti-cholinergics (79%) were given with inhaled corticosteroids (21-67%). Symptoms were perceived to vary throughout the day, affecting quality of life (97%) and mobility (89%). In particular, respiratory symptoms were more severe in the morning (51-92%), leading PPs to adapt treatment (69%). This survey demonstrated that management of COPD by PPs in Belgium is generally in line with the GOLD guidelines 2010 and that they perceive morning symptoms as being frequent and having an impact on patient's life.
Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often undertreated in the general population. A survey of 17 structured questions, delivered to all Belgian pulmonary physicians (PPs) (116 responses), evaluated diagnosis and treatment strategies in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010 and assessed opinions about the importance of diurnal variation of COPD symptoms. All COPD diagnoses (37% new cases) were spirometry confirmed. Main diagnostic parameters were symptoms (99%), external risk factors (99%), clinical examination (97%), exacerbations (96%) and patient mobility (96%). FEV^sub 1^ (forced expiratory volume in 1s) (97%) or FEV^sub 1^/FVC (ratio of FEV^sub 1^ to forced vital capacity) (93%) were used most to assess diagnosis and severity. The 3 most important therapeutic objectives were symptom relief, preventing exacerbations, and improving quality of life; if these were not reached, the preferred strategy (60% of PPs) was adding another medication. Treatment strategies varied with COPD stage: short-acting β^sub 2^-agonists (90%) and shortacting anti-cholinergics (59%) were used for GOLD I disease, whereas for higher stages long-acting β^sub 2^-agonists (36-48%) and long-acting anti-cholinergics (79%) were given with inhaled corticosteroids (21-67%). Symptoms were perceived to vary throughout the day, affecting quality of life (97%) and mobility (89%). In particular, respiratory symptoms were more severe in the morning (51-92%), leading PPs to adapt treatment (69%). This survey demonstrated that management of COPD by PPs in Belgium is generally in line with the GOLD guidelines 2010 and that they perceive morning symptoms as being frequent and having an impact on patient's life. [PUBLICATION ABSTRACT]
Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often under-treated in the general population. A survey of 17 structured questions, delivered to all Belgian pulmonary physicians (PPs) (116 responses), evaluated diagnosis and treatment strategies in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010 and assessed opinions about the importance of diurnal variation of COPD symptoms. All COPD diagnoses (37% new cases) were spirometry confirmed. Main diagnostic parameters were symptoms (99%), external risk factors (99%), clinical examination (97%), exacerbations (96%) and patient mobility (96%). FEV1 (forced expiratory volume in 1s) (97%) or FEV1/FVC (ratio of FEV1 to forced vital capacity) (93%) were used most to assess diagnosis and severity. The 3 most important therapeutic objectives were symptom relief, preventing exacerbations, and improving quality of life; if these were not reached, the preferred strategy (60% of PPs) was adding another medication. Treatment strategies varied with COPD stage: short-acting beta2-agonists (90%) and short-acting anti-cholinergics (59%) were used for GOLD I disease, whereas for higher stages long-acting beta2-agonists (36-48%) and long-acting anti-cholinergics (79%) were given with inhaled corticosteroids (21-67%). Symptoms were perceived to vary throughout the day, affecting quality of life (97%) and mobility (89%). In particular, respiratory symptoms were more severe in the morning (51-92%), leading PPs to adapt treatment (69%). This survey demonstrated that management of COPD by PPs in Belgium is generally in line with the GOLD guidelines 2010 and that they perceive morning symptoms as being frequent and having an impact on patient's life.Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often under-treated in the general population. A survey of 17 structured questions, delivered to all Belgian pulmonary physicians (PPs) (116 responses), evaluated diagnosis and treatment strategies in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010 and assessed opinions about the importance of diurnal variation of COPD symptoms. All COPD diagnoses (37% new cases) were spirometry confirmed. Main diagnostic parameters were symptoms (99%), external risk factors (99%), clinical examination (97%), exacerbations (96%) and patient mobility (96%). FEV1 (forced expiratory volume in 1s) (97%) or FEV1/FVC (ratio of FEV1 to forced vital capacity) (93%) were used most to assess diagnosis and severity. The 3 most important therapeutic objectives were symptom relief, preventing exacerbations, and improving quality of life; if these were not reached, the preferred strategy (60% of PPs) was adding another medication. Treatment strategies varied with COPD stage: short-acting beta2-agonists (90%) and short-acting anti-cholinergics (59%) were used for GOLD I disease, whereas for higher stages long-acting beta2-agonists (36-48%) and long-acting anti-cholinergics (79%) were given with inhaled corticosteroids (21-67%). Symptoms were perceived to vary throughout the day, affecting quality of life (97%) and mobility (89%). In particular, respiratory symptoms were more severe in the morning (51-92%), leading PPs to adapt treatment (69%). This survey demonstrated that management of COPD by PPs in Belgium is generally in line with the GOLD guidelines 2010 and that they perceive morning symptoms as being frequent and having an impact on patient's life.
Author Vandenberghe, H
De Backer, W
Decramer, M
Corhay, JL
Marchand, E
De Vuyst, P
Degryse, JM
Van Craenendonck, V
Buffels, J
Van den Brande, P
Gayan-Ramirez, G
Brusselle, G
Janssens, W
Vincken, W
Author_xml – sequence: 1
  givenname: M
  surname: Decramer
  fullname: Decramer, M
  email: marc.decramer@uz.kuleuven.ac.be
  organization: UZ Leuven Respiratory Division
– sequence: 2
  givenname: G
  surname: Brusselle
  fullname: Brusselle, G
  organization: Ghent University Hospital Department of Respiratory Medicine
– sequence: 3
  givenname: J
  surname: Buffels
  fullname: Buffels, J
  organization: University of Leuven (KU Leuven) Department of Public Health and Primary care
– sequence: 4
  givenname: JL
  surname: Corhay
  fullname: Corhay, JL
  organization: CHU Sart Tilman Department of Pneumology, Liège
– sequence: 5
  givenname: W
  surname: De Backer
  fullname: De Backer, W
  organization: UZ AntwerpEdegem
– sequence: 6
  givenname: JM
  surname: Degryse
  fullname: Degryse, JM
  organization: University of Leuven (KU Leuven) Department of Public Health and Primary care
– sequence: 7
  givenname: W
  surname: Janssens
  fullname: Janssens, W
  organization: UZ Leuven Respiratory Division
– sequence: 8
  givenname: E
  surname: Marchand
  fullname: Marchand, E
  organization: CHU Mont-Godinne Université Catholique de Louvain, Department of Pneumology
– sequence: 9
  givenname: P
  surname: Van den Brande
  fullname: Van den Brande, P
  organization: Emmaüs Hospital Network, Respiratory division, Duffel
– sequence: 10
  givenname: W
  surname: Vincken
  fullname: Vincken, W
  organization: UZ Brussel Vrije Universiteit Brussel, Department of Pneumology
– sequence: 11
  givenname: G
  surname: Gayan-Ramirez
  fullname: Gayan-Ramirez, G
  organization: UZ Leuven Respiratory Division
– sequence: 12
  givenname: V
  surname: Van Craenendonck
  fullname: Van Craenendonck, V
  organization: AstraZenecaMedical Affairs
– sequence: 13
  givenname: H
  surname: Vandenberghe
  fullname: Vandenberghe, H
  organization: AstraZenecaMedical Affairs
– sequence: 14
  givenname: P
  surname: De Vuyst
  fullname: De Vuyst, P
  organization: Erasme Hospital, Department of Pneumology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24579239$$D View this record in MEDLINE/PubMed
BookMark eNptkV1r2zAYhcXoWLOssF8wBLvZjTNJr_yh3QzX8RKDG4d8rAQGQrHl4uJYnexs9N9PJekG23QhCfGcw6tzXqOLznQaobeUTBjl8DFOrifACbxAI8aE7wFAeIFGNIy4BywKLtFV398Tt0DwANgrdMm4HwoGYoS-JcVyiuPbeJUu0vUar7err-nuE54W-DrNZ1m8wMttflMs4tUOL-e7dZa4tzVOiptlvsO32WaON_MUz4p8imfbbJrmmTPCjFDy-Q16Wau211fnc4y2X9JNMvfyYpYlce6VIMTgMVVSXwUqqkNN91FF3dCgVCm4DxDxqq4joD7QICoFE2yvqwDqsCYlUOaHFYMxgpNv2-g7LY3dN_IHk0Y1p_uxvZOqlHstGQsit0XchTRGH06qB2u-H3U_yEPTl7ptVafNsZfUJ5xyAYQ69P1f6L052s79SVLuR6EQhISOenemjvuDruSDbQ7KPsrntB0wOQGlNX1vdS3LZlBDY7rBqqaVlMinRqVrVD41-mfE34Jnz_-g5wyarjb2oH4a21ZyUI-tsbVVXdn0Ev5R_QLxhaT_
CitedBy_id crossref_primary_10_1136_bmjresp_2022_001478
crossref_primary_10_1186_s41606_017_0019_2
crossref_primary_10_1371_journal_pone_0111078
crossref_primary_10_1371_journal_pone_0095305
crossref_primary_10_1016_j_jclinepi_2016_12_012
crossref_primary_10_1038_s41533_020_0163_5
ContentType Journal Article
Copyright 2013 President of the Belgian Society of Internal Medicine and President of the Belgian Society for Clinical Biology 2013
Copyright Acta Clinica Belgica 2013
Copyright_xml – notice: 2013 President of the Belgian Society of Internal Medicine and President of the Belgian Society for Clinical Biology 2013
– notice: Copyright Acta Clinica Belgica 2013
CorporateAuthor on behalf of the COPD Working Group
COPD Working Group
CorporateAuthor_xml – name: on behalf of the COPD Working Group
– name: COPD Working Group
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
Q33
DOI 10.2143/ACB.3403
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
Université de Liège - Open Repository and Bibliography (ORBI)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Research Library Prep

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2295-3337
EndPage 340
ExternalDocumentID oai_orbi_ulg_ac_be_2268_228433
3128108111
24579239
10_2143_ACB_3403
11698992
Genre Research Article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Belgium
GeographicLocations_xml – name: Belgium
GroupedDBID 4.4
7X7
88E
8FI
8FJ
8G5
AAGDL
AALUX
AAMIU
AAPUL
AAQRR
ABBKH
ABEIZ
ABJNI
ABLIJ
ABUPF
ABUWG
ABWVI
ABXYU
ACENM
ACGFS
ACIEZ
ADBBV
ADCVX
AECIN
AENEX
AFKRA
AFRVT
AGDLA
AGFJD
AGRBW
AGYJP
AHMBA
AIJEM
AIRBT
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
ALYBC
AMDAE
AQTUD
ARJSQ
AZQEC
BENPR
BLEHA
BOHLJ
BPHCQ
BVXVI
CCCUG
CCPQU
DWQXO
E01
EBS
EJD
FYUFA
GNUQQ
GUQSH
H13
HCLVR
HMCUK
HZ~
IHR
KYCEM
M1P
M2O
M4Z
O9-
P76
P7A
P7B
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
RNANH
RVRKI
TASJS
TBQAZ
TDBHL
TERGH
TFL
TFW
TUROJ
UEQFS
UHWXJ
UKHRP
53G
AAJKZ
AAORF
AAYXX
ABWCV
ABZEW
ACKZS
ACOPL
ACYZI
ADFOM
ADFZZ
AEIIZ
AFFHD
AFLEI
AJVHN
BRMBE
CITATION
CYYVM
CZDIS
DRXRE
DWTOO
EMOBN
IAO
IEA
IPNFZ
ITC
JENTW
LJTGL
M46
NUSFT
QQXMO
RIG
ADYSH
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
K9.
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
Q33
ID FETCH-LOGICAL-c399t-2ac15a6a8f7e1b8d12863aac9453384dff83153168c9292bed63f7f0c31257d23
IEDL.DBID 7X7
ISICitedReferencesCount 5
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000326144200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1784-3286
2295-3337
IngestDate Sat Nov 29 01:26:30 EST 2025
Fri Sep 05 14:20:41 EDT 2025
Sat Nov 29 14:19:41 EST 2025
Thu Apr 03 07:06:06 EDT 2025
Tue Nov 18 21:37:41 EST 2025
Sat Nov 29 03:55:51 EST 2025
Mon Oct 20 23:45:23 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c399t-2ac15a6a8f7e1b8d12863aac9453384dff83153168c9292bed63f7f0c31257d23
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
scopus-id:2-s2.0-84901485380
PMID 24579239
PQID 1458799007
PQPubID 836352
PageCount 16
ParticipantIDs proquest_miscellaneous_1504149301
crossref_citationtrail_10_2143_ACB_3403
pubmed_primary_24579239
informaworld_taylorfrancis_310_2143_ACB_3403
proquest_journals_1458799007
crossref_primary_10_2143_ACB_3403
liege_orbi_v2_oai_orbi_ulg_ac_be_2268_228433
PublicationCentury 2000
PublicationDate 2013-09-01
PublicationDateYYYYMMDD 2013-09-01
PublicationDate_xml – month: 09
  year: 2013
  text: 2013-09-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Ghent
PublicationTitle Acta clinica belgica (English ed. Online)
PublicationTitleAlternate Acta Clin Belg
PublicationYear 2013
Publisher Taylor & Francis
Taylor & Francis Ltd
Taylor and Francis
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Ltd
– name: Taylor and Francis
SSID ssj0000394632
Score 1.9561424
Snippet Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often undertreated in the general population. A survey of 17 structured...
Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often under-treated in the general population. A survey of 17 structured...
SourceID liege
proquest
pubmed
crossref
informaworld
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 325
SubjectTerms Belgium
Cardiovascular & respiratory systems
Chronic obstructive pulmonary disease
Circadian Rhythm
Clinical medicine
COPD
Female
Guideline Adherence
Human health sciences
Humans
Lung diseases
Male
Meetings
Mortality
Pharmaceutical industry
Physician's Practice Patterns/statistics & numerical data
Physicians
Practice Guidelines as Topic
Practice Patterns, Physicians' - statistics & numerical data
Pulmonary Disease, Chronic Obstructive - diagnosis
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - physiopathology
Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/physiopathology
pulmonary physicians
Quality of life
Questionnaires
Respiratory Function Tests
Risk Factors
Sciences de la santé humaine
Severity of Illness Index
survey
Surveys and Questionnaires
symptoms
Systèmes cardiovasculaire & respiratoire
treatment strategy
SummonAdditionalLinks – databaseName: Taylor & Francis Online Journals
  dbid: TFW
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zi9swEBZlKaUvvY90t0WFQl_q1pZkW-5L8TrOAd4k5Gg2sCBkySoLIVly7O_vSPaGBrYP7YvxMQZ5pNF8o5HnQ-iTrzWXKlYeIdJ44CFKj1MjvSQKtNalYZGsySbiwYBfXiaj5qewbbOt0sbQpi4U4eZqa9yydAwkBNz7tzQ7_0qZK_EJl9Yap535YWHFpwmLHDFZEHPmUcKjuujs0btHbuioSCmg1KXNV_8dcjrX03n6f41-hp40UBOn9dh4jh5Uqxfo0UWTTH-JrrLhqI3TeTrOLfMGnszGP_PFd9we4vO86PbTAR7NCphz0_ECj3qLST-DexOcDS9GxQLP-9MenvZy3B0Wbdyd9dt5YSk8sM18_3iFZp18mvW8hmzBU4BRdh6RKghlJLmJq6DkGvxWRKVUCQNAyJk2hlOYHYOIK0BUpKx0RE1sfEUBIsWa0NfoZLVeVW8RViyhURwk3CQlC3XMFcBM7itjqsqESrbQ5zvdC9VUIreEGEsBEYlVlgBlCausFvp4kLypq2_cI_Plz-4TO7fSYWpaEkHvEXfdK9ab8lrcEmHra7vz_fKXkEqUlQBIyuHAGQXxs7tRIBrr3kK4FPIY3LgfQwMPj8EubbJFrqr1HmRCn0H0CfNnC72pR8_hEwgLbdnG5N2_Nf0UPSaOjMPucDtDJ7vNvnqPHqrb3fV288FZwW95J_4o
  priority: 102
  providerName: Taylor & Francis
Title COPD AWARENESS SURVEY: DO BELGIAN PULMONARY PHYSICIANS COMPLY WITH THE GOLD GUIDELINES 2010?
URI https://www.tandfonline.com/doi/abs/10.2143/ACB.3403
https://www.ncbi.nlm.nih.gov/pubmed/24579239
https://www.proquest.com/docview/1458799007
https://www.proquest.com/docview/1504149301
https://orbi.uliege.be/handle/2268/228433
Volume 68
WOSCitedRecordID wos000326144200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection (ProQuest)
  customDbUrl:
  eissn: 2295-3337
  dateEnd: 20161130
  omitProxy: false
  ssIdentifier: ssj0000394632
  issn: 1784-3286
  databaseCode: 7X7
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2295-3337
  dateEnd: 20161130
  omitProxy: false
  ssIdentifier: ssj0000394632
  issn: 1784-3286
  databaseCode: BENPR
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 2295-3337
  dateEnd: 20161130
  omitProxy: false
  ssIdentifier: ssj0000394632
  issn: 1784-3286
  databaseCode: M2O
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVAWR
  databaseName: Taylor & Francis Online Journals
  customDbUrl:
  eissn: 2295-3337
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000394632
  issn: 1784-3286
  databaseCode: TFW
  dateStart: 19460101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zi9swEBbtbil96X2k3S4qFPpSd21JtuS-LE7iHJDD5GgSWBCybJWFkGxz7O_vyHbSFrZ96YvwMRiZGc18mhHzIfTRzTKhNNcOIco4ECFSR1CjnDDwsixLDQtUSTbBBwMxn4dJlXDbVscqDz6xcNTZWtsc-YXHfMHBdbr88uaHY1mjbHW1otC4j04tbba1cz7nxxyLS0MWFBxlHhfMoUQEZf9ZAijhImrUv1B2YMuqItIf_UoBsC5t6frv6LOIQq0n_zv_p-hxhT9xVBrMM3QvXz1HD_tVhf0FumoMkyaOZtEotnQceDwdfYsXX3FziOtxr92NBjiZ9sARR6MFTjqLcbcBz8a4MewnvQWedScdPOnEuD3sNXF72m3GPcvrgW05_PIlmrbiSaPjVAwMjgbgsnOI0p6vAiUMz71UZBDMAqqUDhmgRMEyYwQFl-kFQgPMImmeBdRw42oKuIlnhL5CJ6v1Kn-DsGYhDbgXChOmzM-40IA9hauNyXPja1VDnw5akLpqT25ZMpYStilWXxL0Ja2-aujDUfKmbMlxh8zn3xUpd0X6w5RcJZLeIV4oWq436bW8JdI23S6u98vvUmmZ5hJwqoBBMAriZwcdy2rJb-UvBcMEj69hsdoKjFrl6z3I-C6DLSk41Rp6XdrR8RcI820vx_Dtvz_-Dj0iBSOHPeZ2hk52m33-Hj3Qt7vr7ea8sP9iFOfotB4PkhHc9ckQxklr9hMK_Ag_
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3ZbtNAFB1VBQEv7EugwCCBeMHUy9gzRkKVm7hJVGdRljaRkIbxjAdVipKSpYif4hu54yWAVHjrAy-WZV9Ztuf43DOL70Hota0UE5JKy3WFtiBDpBbztLDCwFFKpZoEojCboN0um0zC_g76Uf0LY5ZVVpyYE7VaSDNGvu8Qn1GgTpsenH-1jGuUmV2tLDQKWBxn379Bl231sd2A9n3jukfxqN6ySlcBS0IyXluukI4vAsE0zZyUKSDowBNChgSUDyNKa-YBDTgBkyAd3DRTgaeptqUHWoAqU-gAKP8a8Dg1nT06odsxHdsLSZB7ojmUEcuDKxf1bl1QJftR_fC9Ryp3rjID_lEfFQTyzEyV_13t5lnv6M7_9r7uotulvsZR8UHcQzvZ_D660SlXEDxAn-q9fgNHp9EgNnYjeDgenMTTD7jRw4dx0mxHXdwfJ5BoosEU91vTYbsOx4a43uv0kyk-bY9aeNSKcbOXNHBz3G7EifEtwWa6_-AhGl_Jsz1Cu_PFPHuCsCShF1AnZDpMia8ok6CtmS21zjLtS1FDb6tW57Isv25cQGYcumEGHxzwwQ0-aujVNvK8KDlyScy734HD1_nwji68WLh3SXgOLL5Ypmf8wuWmqHi-v5l94ULyNOOgwxlsGPEgfK_CFC8pbcV_AQpucHsayMjMMIl5tthAjG8T6HJD0qihxwVut4_gEt_Uqgyf_vviL9HN1qiTcGi842folpu7j5glfXtod73cZM_RdXmxPlstX-TfHkafrxq8PwG6r19i
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamDk28cL8UBhgJxAuhuTixg4SmtEkvWtdGvbBVQjKOE6NJVTt6GeKv8es4zqWANHjbAy9RlBxFcfz5nM_2yfkQemWmKROSSsO2hTIgQiQGc5QwfM9K0zRRxBOF2AQdDNjZmR_voR_VvzA6rbLyibmjTpdSr5E3LOIyCq7TpA1VpkXEYfvo4quhFaT0Tmslp1FA5Dj7_g2mb-sPvRD6-rVtt6NJq2uUCgOGhMC8MWwhLVd4gimaWQlLwVl7jhDSJ8CCGEmVYg64BMtjEmiEnWSp5yiqTOkAL6CpLnoA7n-fAskgNbTfjAbxaLfCYzo-8XKFNIsyYjjw7KL6rQ0cpRG0mu8cUml1lfHwj2qpQJfneuP879w3j4Ht2__z17uDbpXMGwfFULmL9rLFPXRwUuYW3EefWsM4xMFpMIq0EAkeT0cfo9l7HA5xM-p3esEAx9M-hKBgNMNxdzbuteDaGLeGJ3F_hk97ky6edCPcGfZD3Jn2wqivFU2wTgQ4eoCm19K2h6i2WC6yxwhL4jsetXym_IS4KWUSWDczpVJZplwp6uhNhQAuy8LsWh9kzmGCprHCAStcY6WOXu4sL4piJFfYvP0dRHyTL_yoQqWFO1eY5yDjy1Vyzi9trsuN5-fb-RcuJE8yDgydwYERB8wPK3zx0tmt-S9wwQvuboOb0ntPYpEtt2DjmgQm4xBO6uhRgeFdE2zi6iqW_pN_P_wFOgDMcui746fopp3Lkuhcv0NU26y22TN0Q15uzter5-VAxOjzdaP3J2qzaYI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COPD+AWARENESS+SURVEY%3A+DO+BELGIAN+PULMONARY+PHYSICIANS+COMPLY+WITH+THE+GOLD+GUIDELINES+2010%3F&rft.jtitle=Acta+clinica+belgica+%28English+ed.+Online%29&rft.au=Decramer%2C+M&rft.au=Brusselle%2C+G&rft.au=Buffels%2C+J&rft.au=Corhay%2C+JL&rft.date=2013-09-01&rft.issn=1784-3286&rft.eissn=2295-3337&rft.volume=68&rft.issue=5&rft.spage=325&rft.epage=340&rft_id=info:doi/10.2143%2FACB.3403&rft.externalDBID=n%2Fa&rft.externalDocID=10_2143_ACB_3403
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1784-3286&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1784-3286&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1784-3286&client=summon